SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares

$CVET
Other Pharmaceuticals
Health Care
Get the next $CVET alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
CD&R Investment Associates IX, Ltd.

(Last) (First) (Middle)
C/O M+C CORPORATE SERVICES LIMITED
P.O. BOX 309 UGLAND HSE, SOUTH CHURCH ST

(Street)
GEORGE TOWN E9 KY1-1104

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
COVETRUS, INC. [ CVET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/13/2022 J(1)(2)(3)(4) 33,670,541 D (1)(2)(3)(4) 0 I By affiliate(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
CD&R Investment Associates IX, Ltd.

(Last) (First) (Middle)
C/O M+C CORPORATE SERVICES LIMITED
P.O. BOX 309 UGLAND HSE, SOUTH CHURCH ST

(Street)
GEORGE TOWN E9 KY1-1104

(City) (State) (Zip)
1. Name and Address of Reporting Person*
CD&R VFC Holdings L.P.

(Last) (First) (Middle)
C/O M+C CORPORATE SERVICES LIMITED
P.O. BOX 309 UGLAND HSE, SOUTH CHURCH ST

(Street)
GEORGE TOWN E9 KY1-1104

(City) (State) (Zip)
Explanation of Responses:
1. On October 13, 2022, Covetrus, Inc. (the "Issuer"), Corgi Bidco, Inc. ("Parent") and Corgi Merger Sub, Inc. ("Merger Sub") completed the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 24, 2022 (the "Merger Agreement"), by and among the Issuer, Parent and Merger Sub. Pursuant to the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Surviving Corporation"). Immediately prior to the Merger, CD&R VFC Holdings L.P. ("CD&R Holdings") contributed all of its Shares (as defined below) to a parent entity of Parent (with such Shares subsequently contributed to Parent) pursuant to the Support and Rollover Agreement, dated as of May 24, 2022, by and among the Issuer, Parent and CD&R Holdings (the "Contribution").
2. At the effective time of the Merger (the "Effective Time"), in accordance with the terms and conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (the "Shares") outstanding immediately prior to the Effective Time (other than Shares owned by (i) Parent or Merger Sub or any of their respective subsidiaries (including the Shares indirectly transferred by CD&R Holdings to Parent as part of the Contribution), (ii) the Issuer as treasury stock (the Shares referred to in (i) and (ii), the "Excluded Shares") and (iii) the Issuer stockholders (the "Dissenting Stockholders") who had perfected and not withdrawn a demand for appraisal rights in accordance with Section 262 of the Delaware General Corporation Law (the "DGCL")), was converted into the right to receive cash in an amount equal to $21.00 per share, without interest and subject to any required withholding taxes (the "Merger Consideration").
3. At the Effective Time, the Excluded Shares were cancelled and ceased to exist without payment of any consideration therefor and Dissenting Stockholders became entitled to receive only the payment provided by Section 262 of the DGCL with respect to Shares owned by such Dissenting Stockholder, provided that if, after the Effective Time, any person who otherwise would be deemed a Dissenting Stockholder shall have failed to properly perfect or shall have effectively withdrawn or lost the right to dissent under Section 262 of the DGCL or if a court of competent jurisdiction shall finally determine that the Dissenting Stockholder is not entitled to relief provided by Section 262 of the DGCL with respect to any Shares, such Shares shall thereupon be treated as though such Shares had been converted, as of the Effective Time, into the right to receive the Merger Consideration without interest and less any required tax withholding.
4. Following the Contribution and the Merger, the Reporting Persons no longer beneficially own any Shares.
5. These securities were owned directly by CD&R Holdings. CD&R Investment Associates IX, Ltd., as the general partner of CD&R Holdings, may have been deemed to beneficially own the Shares held by CD&R Holdings. CD&R Investment Associates IX, Ltd. expressly disclaims beneficial ownership of Shares that were held by CD&R Holdings, except to the extent of its pecuniary interest therein.
Remarks:
CD&R Investment Associates IX, Ltd., By: /s/ Rima Simson, Vice President, Treasurer and Secretary 10/13/2022
CD&R VFC Holdings, L.P., By: CD&R Investment Associates IX, Ltd., general partner; By: /s/ Rima Simson, Vice President, Treasurer and Secretary 10/13/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CVET alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CVET

DatePrice TargetRatingAnalyst
6/13/2022$22.00Buy → Hold
Stifel
5/23/2022Outperform → Mkt Perform
Raymond James
11/18/2021$19.00Equal-Weight
Morgan Stanley
11/5/2021$37.00 → $27.00Outperform
Raymond James
8/9/2021$46.00 → $38.00Overweight
Barclays
8/6/2021$38.00 → $37.00Outperform
Raymond James
8/5/2021$29.00Neutral
Credit Suisse
7/12/2021$30.00Neutral → Buy
Guggenheim
More analyst ratings

$CVET
Press Releases

Fastest customizable press release news feed in the world

See more
  • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

    Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

    $SEMR
    $CVET
    Computer Software: Prepackaged Software
    Technology
    Other Pharmaceuticals
    Health Care
  • Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

    NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

    $CVET
    $MLKN
    $SPGI
    $WLK
    Other Pharmaceuticals
    Health Care
    Office Equipment/Supplies/Services
    Consumer Discretionary
  • Covetrus Names Michelle Bonfilio as Chief People Officer

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

    $CVET
    Other Pharmaceuticals
    Health Care

$CVET
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CVET
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CVET
SEC Filings

See more

$CVET
Leadership Updates

Live Leadership Updates

See more
  • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

    Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

    $SEMR
    $CVET
    Computer Software: Prepackaged Software
    Technology
    Other Pharmaceuticals
    Health Care
  • Covetrus Names Michelle Bonfilio as Chief People Officer

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

    $CVET
    Other Pharmaceuticals
    Health Care
  • Covetrus Names Margie B. Pritchard General Counsel

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

    $CVET
    Other Pharmaceuticals
    Health Care

$CVET
Financials

Live finance-specific insights

See more
  • Covetrus Announces Financial Results for Second Quarter of 2022

    Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

    $CVET
    Other Pharmaceuticals
    Health Care
  • Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

    $CVET
    Other Pharmaceuticals
    Health Care
  • Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

    Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

    $CVET
    Other Pharmaceuticals
    Health Care

$CVET
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more